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1前言
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world.
Owing to its heterogeneity and the development of multidrug resistance phenotypes,
HCC is refractory to conventional treatment. The use of conditionally replicating
viruses, including adenovirus, has offered a promising platform for selective cancer
treatment.
研究目的
The aims of this study are to exploit tumor selective and liver-specific
replication-selective oncolytic adenoviruses for the treatment of HCC. The one we
choose for tissue-specific replication is transthyretin. Transthyretin is a thyroid
hormone transport protein that is secreted by hepatocytes into the serum and by
choroid plexus into the cerebrospinal fluid. A 200-nucleotide sequence from the
5’end to the cap site is highly conserved between mouse and human genes.
Furthermore, sequence alignment indicated an 80% homology with the human gene
at the protein level. Deletion analysis identified a crucial element in the 5’-flanking
regulatory region for liver cell-specific expression in mouse liver and human
hepatoma cell lines. The transthyretin promoter has been used to study the function
of particular genes in liver from transgenic mice. These findings suggest that
transthyretin may serve as a specific marker for targeting liver-derived tumors.
文獻探討
One of the most studied oncolytic adenoviruses, ONYX-015, an E1B-55
kD-deleted adenovirus, can selectively replicate in tumor cells while sparing normal
cells for cancer treatment. Several clinical trials, such as head and neck cancer,
ovarian cancer, pancreatic cancer, have supported the therapeutic use of ONYX-015
for the treatment of solid tumors [1-3]. Clinical trials in patients with primary liver
cancers or gastrointestinal carcinoma metastatic to liver have also been reported [4-6].
Despite such encouraging results, clinical trials using oncolytic adenoviruses alone
were so far disappointing [7]. To increase viral cytotoxicity, numerous efforts have
been made to improve the therapeutic efficacy of oncolytic adenoviruses by
expressing transgenes [8-10] or modifying viral fibers to extend viral tropism [11]. To
target oncolytic adenoviruses to specific tumors, tumor- or tissue-specific promoters
have been employed to control the expression of early viral genes, such as E1A, to
achieve tumor-specific adenoviral replication. E1B-55 kD-deleted adenoviruses
driven by the albumin orα-fetoprotein (AFP) promoter have been shown to kill HCC
cells [12-15].
2研究方法
In this study, we constructed a liver-specific E1B-55kD-deleted adenovirus,
designated Ad5WS2, under the control of the transthyretin promoter. The antitumor
activity of Ad5WS2 in vitro and in vivo was tested.
Cell lines and Mice. The ML-1 mouse liver cell line was originally established from
hepatocytes of BALB/c mice. The LL2 murine Lewis lung cancer cell line was
obtained from the American Type Culture Collection. HT1376 (human bladder cancer
cell line) and SK-Hep1, Hep3B (human HCC cell lines), as well as Chang liver
(transformed human hepatocyte cell line), 293, ML-1 and LL2 cells were cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, 1%
glutamine and 50 μg/ml gentamicin at 37℃ in 5% CO2. Female BALB/c mice and
C57BL/6 mice at the age of 7 weeks were obtained from the Laboratory Animal
Center of the National Cheng Kung University. The experimental protocol adhered to
the rules of the Animal Protection Act of Taiwan and was approved by the Laboratory
Animal Care and Use Committee of the National Cheng Kung University.
Construction of Recombinant Adenoviruses. The E1B-55 kD-deleted adenovirus,
designated Ad5WS1, was constructed. The promoter region of E1 gene was modified
for construction of the hepatocellular carcinoma- specific adenovirus variant,
Ad5WS2. To insert a multiple cloning site prior to E1 gene, the adenovirus E1 region
from base 4261 to 4921 was generated by the polymerase chain reaction (PCR) using
pAd5WS1 as a template. The resulting 700 bp fragment restricted with NotI and SacI
was cloned into the pBluescript II SK(+/-) to generate pBSII-0.7. The adenovirus E1
region from base 2761 to 4261 was generated by PCR using pAd5WS1 as a template.
The resulting 1700 bp fragment restricted with XhoI and KpnI was cloned into the
XhoI and KpnI sites of pBSII-0.7 to generate pBSII-0.7-1.7. The 2700 bp fragment of
pBSII-0.7-1.7 was digested with NotI and KpnI and cloned into pAd5WS1 to generate
pAd5YS. The 300 bp fragment of human transthyretin promoter from pAP-TTRBSV
was digested with HindIII and cloned into the HindIII sites of pAd5YS to generate
pTTRp/YS. The resulting 3000 bp fragment of pTTRp/YS was digested with BsrGI
and MunI and cloned into pShuttle to generate pTTRp/YS/PS. The Ad5WS2 virus
was generated using Ad Easy system. Briefly, the pTTRp/YS/PS was linearized with
PmeI, and subsequently cotransformed into E.coli, BJ5183 with an adenoviral
backbone plasmid, pAdEasy-1. The recombinant pTTRp/YS/PS was then cleaved
with PacI to liberate linear adenoviral genomes, and then transfected into a packaging
cell line, 293 cells by lipofectin (Gibco BRL, Rockville, MD) to generate a
replication-competent adenovirus, Ad5WS2. 293 cells were used for virus
propagation and as a positive control in the viral replication assay.
Analysis of transthyretin. The transcription activity of gene was assayed as
3previously described. Briefly, human bladder cancer cells, HCC cells, Chang Liver
cells as well as mice cells grown in 6-well plates were cotransfected with 2 μg of
pTTRp-Luc containing a luciferase expression cassette driven by human transthyretin
gene promoter, and 1μg of pTRELacZ by lipofectin. Cell lysates were harvested 48 h
after transfection and the luciferase activities were determined.
Assay of viral replication, CPE and cell viability. Confluent cells in 6-well plates
were infected with either Ad5WS2 or Ad5WT at an MOI of 10. Viruses harvested
from both the supernatant and cell lysate at 53 h postinfection were pooled and titered
on 293 cells for 50% tissue culture infective dose (TCID50) calculated by the
Reed-Muench Method. The relative virus replication efficiency was calculated by the
following equation as described previously. (Virus titer in cells infected with
Ad5WS2/virus titer in cells infected with Ad5WT) × (virus titer in 293 infected with
Ad5WT/virus titer in cells infected with Ad5WS2) ×100. The cytolytic effect of
Ad5WS2 was tested by infecting cells with Ad5WS2, Ad5WS1 and wild type
adenovirus type 5 (Ad5WT) with serial dilutions of the indicated viruses ranging from
0.01 to 1 multiplicities of infection (MOIs) for 2 h. Cells were observed daily for CPE.
Once the CPE was evident, which took 4 to 7 days, cells were stained with 10%
formalin/0.05% crystal violet solution. The viable cell numbers were also determined
in cells seeded in 6-well plates after 3 days of virus infection at an MOI of 2 by trypan
blue exclusion.
In vivo antitumor efficacy. ML-1 and LL2 cells (1 ×106) were inoculated s.c. into the
right flank of BALB/c and C57/BL6 mice, respectively, at day 0. Twelve days after
tumor cell inoculation, when tumors were pabable, eight mice were randomly
allocated to various treatment groups. Mice were treated by i.t. injection of either
virus at a dose of 2 ×107 PFU every other day from day 12 to day 20. Tumors were
measured once a week in two perpendicular axes with a tissue caliper and the tumor
volume was calculated as: (length of tumor) ×(width of tumor)2 ×0.45. To establish
an orthotopic hepatic carcinoma model, BALB/c mice were anesthetized with 90
mg/kg of ketamine hydrochloride. Their abdominal cavities were opened to expose
liver lobes, and ML-1 cells (2 ×105) were injected into the left liver lobe at day 0
using a 10-μl syringe (Terumo, Elkton, MD, USA). The needle hole was then sealed
with electric coagulator immediately after withdrawal of the needle to avoid leakage
of the injected fluid. The incision was subsequently sutured. All mice were monitored
for survival after tumor inoculation. All mice were monitored for survival after tumor
inoculation.
Statistical analysis. Tumor volumes were compared using an unpaired, two-tailed
Student’s t test. The survival analysis was performed using the Kaplan-Meier survival
curve and the log-rank test. Any P values less than 0.05 is regarded as statistically
4significant.
結果與討論
I. Tissue Specificity of the Transthyretin Promoter
To determine its tissue specificity, the activity of the transthyretin promoter was
determined with the luciferase reporter assay in cells from different origins. The cell
lines used included human HCC (Hep3B and SK-Hep1), human bladder cancer
(HT1376), murine HCC (ML-1), and murine lung cancer (Lewis lung carcinoma, LL2)
cells. As shown in Fig. 1, the transthyretin promoter was active in liver cells, with
highest activity in Hep3B cells and moderate activity in Chang liver, ML-1, and
SK-Hep1 cells. Notably, the transthyretin promoter activity in ML-1 cells was
comparable to that in Chang liver cells, suggesting that the human tranthyretin
promoter may have used mouse transcription machinery as efficiently as using the
human counterpart. However, HT1376 and LL2 cells had very low, if any,
transcriptional activity of the transthyretin promoter. To further investigate the
capacity of Ad5WS2 replication in HCC and other cancer cell lines, the amount of
Ad5WS2 produced at 53 h postinfection was normalized against the amount of a
wild-type adenovirus type 5 (Ad5WT) produced in the same cells (Fig. 2). Ad5WT5
produced 1.87-fold higher viruses than Ad5WS2 in 293 cells (data not shown). Fig. 2
shows that Hep3B produced the highest viral titer when infected with Ad5WS2
compared with Ad5WT, followed by SK-Hep1 and ML-1 cells. By contrast, the
production rate of Ad5WS2 reached only 0.41% and 16% of Ad5WT in HT1376 and
LL2, respectively, which exhibited a relatively resistant phenotype to Ad5WS2
infection. Notably, Chang liver cells, the immortalized human hepatocyte, in which
transthyretin promoter was active, were also resistant to Ad5WS2 infection (2.35%
relative to Ad5WT). The relative production rate of Ad5WS2 at 26 h postinfection
was similar to that at 53 h postinfection (data not shown). These results indicate that
gene expression driven by the TTR promoter was specific to liver tumor cells.
II. Ad5WS2 Caused Severe Cytolytic Effect in HCC Cells, But Highly Attenuated
in Non-liver Cells
To confirm restriction of Ad5WS2 replication, we performed cytotoxicity assay in
various cancer cells. Ad5WS2 caused complete cytolysis in ML-1 cells within 5 days,
at a multiplicity of infection (MOI) of 0.1 (Fig. 3). Either Ad5WS2 or Ad5WS1
caused cytopathic effect (CPE) in HCC cells, including Hep3B, SK-Hep1, and ML-1
cells. Notably, Ad5WS2 appeared to produce more CPE than Ad5WS1 in Hep3B and
SK-Hep1 cells. Neither non-liver cancer cells (HT1376 and LL2 cells) nor Chang
liver cells showed significant CPE within 7 days when infected with Ad5WS2, despite
of the fact that Ad5WT and Ad5WS1 induced similar degrees of CPE in LL2 and
5HT1376 cells. As expected, while Chang liver cells were susceptible to Ad5WT
infection, they were resistant to Ad5WS1-induced cytolysis. Cell viability was also
measured by trypan blue exclusion 3 days after infection with Ad5WS2 or Ad5WS1 at
an MOI of 2 (Fig. 4). The viability of Hep3B or SK-Hep1 cells infected with
Ad5WS2 was lower than that infected with Ad5WS1. Furthermore, the viability of
ML-1 cells infected with Ad5WS2 or Ad5WS1 did not differ significantly from that
of the mock-infected counterpart. Notably, neither Ad5WS2 nor Ad5WS1 infection
affected cell survival of Chang liver cells as compared with mock-infected cells. By
contrast, while Ad5WS1 induced significant cell death in HT1376 and LL2 cells,
Ad5WS2 did not cause significant cell death in these cells. Taken together, these
results show that Ad5WS2 replicated more efficiently in and targeted HCC cells, but
highly attenuated in non-liver cells. The transthyretin promoter allowed E1B-55
kD-deleted adenovirus specifically to replicate in HCC cells.
III. Antitumor Efficacy of Ad5WS2 in Subcutaneous Murine Tumor Models
To demonstrate the antitumor effect of Ad5WS2 on HCC, tumor growth was
determined after intratumoral injection of Ad5WS2 or Ad5WS1 into BALB/C and
C57BL/6 mice bearing subcutaneous ML-1 and LL2 tumors, respectively. The growth
of ML-1 tumors was significantly retarded in Ad5WS2-treated (P=0.007) or
Ad5WS1-treated (P=0.002) mice compared with that in PBS-treated mice (Fig. 5A).
However, in LL2-tumor bearing mice, while Ad5WS1 significantly retarded tumor
growth (P=0.00007), Ad5WS2 only exhibited marginal antitumor effect compared
with PBS treatment ((P=0.09) (Fig. 5B). These results show that Ad5WS2 was
cytolytic to tumor cells in which transthyretin promoter was active, resulting in
suppressing tumor cell growth. The cell type-specific cytolysis of Ad5WS2 observed
in vivo was consistent with that observed in vitro.
IV. Antitumor Efficacy of Ad5WS2 in Orthotopic Murine Tumor Models
To further examine the targeting efficacy of Ad5WS2 to tumors, mice bearing
orthotopic ML-1 tumors were administered intravenously with Ad5WS2.
Ad5WS2-treated mice exhibited enhanced survival compared to PBS-treated
(P=0.008) or Ad5WS1-treated (P=0.0257) animals. Three of seven Ad5WS2-treated
mice remained alive at the time of sacrifice (Fig. 6).
Adenoviruses are attractive for cancer gene therapy because of their potential to
transduce to tumor sites. However, the major challenges are efficacy and safety. Our
previous results have shown that Ad5WS1 could induce cytolysis in primary bladder
cancer and HCC cells. Ad5WS1 is an oncolytic adenovirus with a deletion in the
E1B-55 kD gene and able to target tumor cells. To increase tumor specificity of the
virus, accordingly, we replaced the E1A promoter of Ad5WS1 with a liver-specific
TTR promoter for targeting to HCC. Three features were responsible for the safety
6and efficacy of Ad5WS2. First, the 5’-terminal sequences containing E1A enhancer
was deleted to optimize the selectivity of Ad5WS2. Second, it could only replicate
efficiently in liver tissue where the thranthyretin promoter was active. Third, it
conferred tumor-selective replication and cytolysis due to E1B-55 kD deletion.
Several studies have focused on the use of the AFP promoter to target virus to liver
tumors. Although the AFP promoter is potent, AFP-producing hepatocytes are quite
often present in inflamed liver associated with hepatitis and cirrhotic hepatocytes.
Ad5WS2 may be more specifically target to liver tumor cells but spare inflamed and
cirrhotic hepatocytes. In addition, as it was estimated that ~25% of HCC patients do
not have elevated AFP, AFP promoter-driven oncolytic viruses may not be efficacious
for HCC patients without AFP expression. Our results show that the cytolytic effect
induced by Ad5WS2 in non-AFP producing cells, such as SK-Hep1 cells, which were
very resistant to the infection of AFP promoter-driven adenovirus, was even higher
than that induced by Ad5WS1. Ad5WS2 replicated more efficiently than Ad5WS1 in
human HCC cells, where their transthyretin promoters were active. Based on our in
vitro study, Ad5WS2 could achieve as well or better cytolytic effect in liver-tumor
cells as Ad5WS1. Utilizing liver-tumor specific replication adenovirus, smaller
amount of viruses would be required for therapy to achieve the same or even better
antitumor effect.
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Figure 1 Selective expression of transthyretin
promoter. Cells were transiently cotransfected with
pTTRp-luc and pTRELacZ. Luciferase and
-galactosidase activities were analyzed after
transfection, and luciferase activity was normalized
with -galactosidase activity. Relative luciferase
activity was indicated by comparing each cell line
with Chang liver cell line.
Figure 2 Cells were infected with Ad5WS2 or Ad5WT at
an MOI of 10. Fifty-three hours post-infection, the viral
titers were determined on 293 cells by TCID50 method.
The amount of Ad5WS2 produced was normalized
against the amount of Ad5WT produced in the same cells.
Relative viral production was indicated by comparing
each cell line with 293 cells.
F i g u r e 3
C P E i n
various cell
lines after
A d 5 W S 2
infection at
d i f f e r e n t
MOIs. Cells
w e r e
i n f e c t e d
w i t h
increasing
M O I s
(0.01-1) and
moni tored
d a i l y f o r
C P E .
Figure 4 Cells
wer e i n f ec t ed
with Ad5WS2 or
Ad5WS1 at an
MOI of 2. The
v i a b l e c e l l
n umb ers were
determined after
3 days by trypan
blue exclusion.
E a c h p o i n t
rep resen ts the
average of three
determinations ±
S.D. * and ***
s t a t i s t i c a l l y
s i g n i f i c a n t
d i f f e r e n c e s
b e t w e e n t h e
i n d i c a t e d 2
groups (P＜0.05
and P＜0 .001 ,
r e s p ec t i v e l y) .
Figure 5 ML-1 (A) and LL2 (B) cells (1 ×106) were inoculated s.c. into
the flank of BALB/c and C57/BL6, respectively, at day 0. At day 12,
groups of 8 mice were treated i.t. with viruses at a dose of 2 ×107 PFU
every other day from day 12 to day 20. The tumor volume is presented as
mean + S.E. ** and *** statistically significant differences between the
indicated 2 groups (P＜0.01 and P＜0.001, respectively).
Figure 6 ML-1 cells (2 ×105) were
injected into the left liver lobe at day 0.
Group of 6-7 mice bearing orthotopic
ML-1 tumors were then injected i.v. with
viruses at a dose of 2 × 107 PFU every
other day from day 15 to day 19. Survival
of animals was determined by log rank test
of a Kaplan-Meier survival curve.
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9計畫成果自評
We have successfully studied the antitumor effect of the tissue-specific promoter
driven E1B-deleted oncolytic adenovirus in the subcutaneous and orthotopic murine
liver tumor models. We are now testing the antitumor activity of this virus in the
ascites liver tumor models and evaluate the safety and efficacy of this virus
comparing to the original E1B-deleted oncolytic adenovirus. The whole data will be
combined and prepared for submission to one journal. We believe these pre-clinical
studies will provide the scientific foundation for future development of recombinant
oncolytic adenovirus as an effective therapeutic agent for primary HCC and ascites
associated HCC.
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發表論文題目
TUMOR TARGETING OF AN ONCOLYTIC ADENOVIRUS REGULATED BY TRANSTHYRETIN PROMOTER
ON MALIGNANT ASCITES ASSOCIATED WITH HEPATOCELLULAR CARCINOMA
一、參加會議經過
The meeting was held at Nippon Medical School, Sendagi, Tokyo, on 24-26 August,
2006. The program includes the invited lectures, technical seminars, and international
symposium. The main topics were focused on the aspects of gene transfer and gene therapy.
This meeting was held continuously with different sessions and all day from 8:30 to 18:00
each day. Most speakers presented in English. The time for my oral presentation is 10 minutes
and 3 minutes discussion. They also have a reception party at the first day of meeting and a
boat cruise in Tokyo Bay on August 25.
二、與會心得
This was the first time for me to have a chance to attend the international meeting of gene
therapy. It was a pleasure to meet persons working in the similar area. It was also inspiring to
know the advancement of other gene therapy strategy. In this meeting, cancer therapy and
vector development were still the main focuses for study. However, the research for stem cell
was prospective and provided me a good direction for therapy in the future. I was asked three
questions in my oral presentation, one was about the details regarding to the experiment, and
the other twos were about the therapeutic safety and efficacy of virus. It was challenging but a
useful training for young scientist. Just like the president of the conference said: gene therapy
is not an established therapeutic strategy, but has extremely huge potential. This will be the
reason to attract me to do research in the future. Thank you for NSC providing such kind of
chance to me and having this wonderful experience!
